In this context, several blood-based inflammatory markers like the neutrophil, lymphocyte, monocyte, and platelet count; albumin level; alcohol dehydrogenase; C-reactive protein (CRP), and combinations like neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) have been used to predict outcomes in patients with cancer (8–10). The gene discussed is CRP; the disease is cancer.